251 related articles for article (PubMed ID: 14726653)
1. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.
Kardosh A; Blumenthal M; Wang WJ; Chen TC; Schönthal AH
Cancer Biol Ther; 2004 Jan; 3(1):55-62. PubMed ID: 14726653
[TBL] [Abstract][Full Text] [Related]
2. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.
Grösch S; Tegeder I; Niederberger E; Bräutigam L; Geisslinger G
FASEB J; 2001 Dec; 15(14):2742-4. PubMed ID: 11606477
[TBL] [Abstract][Full Text] [Related]
3. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
4. Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.
Pinheiro RM; Calixto JB
Inflamm Res; 2002 Dec; 51(12):603-10. PubMed ID: 12558194
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines.
Hashitani S; Urade M; Nishimura N; Maeda T; Takaoka K; Noguchi K; Sakurai K
Int J Oncol; 2003 Sep; 23(3):665-72. PubMed ID: 12888902
[TBL] [Abstract][Full Text] [Related]
6. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells.
Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G
Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
Patel MI; Subbaramaiah K; Du B; Chang M; Yang P; Newman RA; Cordon-Cardo C; Thaler HT; Dannenberg AJ
Clin Cancer Res; 2005 Mar; 11(5):1999-2007. PubMed ID: 15756026
[TBL] [Abstract][Full Text] [Related]
9. COX-2-Specific inhibitors--the emergence of a new class of analgesic and anti-inflammatory drugs.
Everts B; Währborg P; Hedner T
Clin Rheumatol; 2000; 19(5):331-43. PubMed ID: 11055820
[TBL] [Abstract][Full Text] [Related]
10. First and second generations of COX-2 selective inhibitors.
de Leval X; Julémont F; Benoit V; Frederich M; Pirotte B; Dogné JM
Mini Rev Med Chem; 2004 Aug; 4(6):597-601. PubMed ID: 15279593
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel cyclooxygenase-2 selective inhibitors using pharmacophore models.
Palomer A; Cabré F; Pascual J; Campos J; Trujillo MA; Entrena A; Gallo MA; García L; Mauleón D; Espinosa A
J Med Chem; 2002 Mar; 45(7):1402-11. PubMed ID: 11906281
[TBL] [Abstract][Full Text] [Related]
12. A new class of COX-2 inhibitors offer an alternative to NSAIDS in pain management after spinal surgery.
Reuben SS
Spine (Phila Pa 1976); 2001 Jul; 26(13):1505-6. PubMed ID: 11458162
[No Abstract] [Full Text] [Related]
13. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment.
Swamy MV; Cooma I; Patlolla JM; Simi B; Reddy BS; Rao CV
Mol Cancer Ther; 2004 Feb; 3(2):215-21. PubMed ID: 14985462
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer.
Fu SL; Wu YL; Zhang YP; Qiao MM; Chen Y
World J Gastroenterol; 2004 Jul; 10(13):1971-4. PubMed ID: 15222049
[TBL] [Abstract][Full Text] [Related]
15. COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Majchrzak-Celińska A; Misiorek JO; Kruhlenia N; Przybyl L; Kleszcz R; Rolle K; Krajka-Kuźniak V
BMC Cancer; 2021 May; 21(1):493. PubMed ID: 33941107
[TBL] [Abstract][Full Text] [Related]
16. Effects of NSAIDs on proliferation of gastric cancer cells in vitro: possible implication of cyclooxygenase-2 in cancer development.
Sawaoka H; Kawano S; Tsuji S; Tsujii M; Murata H; Hori M
J Clin Gastroenterol; 1998; 27 Suppl 1():S47-52. PubMed ID: 9872498
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Badawi AF; Eldeen MB; Liu Y; Ross EA; Badr MZ
Cancer Res; 2004 Feb; 64(3):1181-9. PubMed ID: 14871855
[TBL] [Abstract][Full Text] [Related]
18. COX-2 inhibitors.
Hawkey CJ
Lancet; 1999 Jan; 353(9149):307-14. PubMed ID: 9929039
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis in rheumatoid synovial fibroblasts by celecoxib, but not by other selective cyclooxygenase 2 inhibitors.
Kusunoki N; Yamazaki R; Kawai S
Arthritis Rheum; 2002 Dec; 46(12):3159-67. PubMed ID: 12483719
[TBL] [Abstract][Full Text] [Related]
20. The new NSAIDs: cox-2 inhibitors.
Capriotti T
Medsurg Nurs; 2000 Dec; 9(6):313-7. PubMed ID: 11904867
[No Abstract] [Full Text] [Related]
[Next] [New Search]
